Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.67 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.67 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.61 |
| ▸ | TP53 | P04637 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | CASP1 | P29466 | 2/20 | 0.61 |
| ▸ | CASP7 | P55210 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | BACE1 | P56817 | 2/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17786540 | 0.91 | CSNK2A2 (0.55) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL7639410 | 0.90 | CSNK2A2 (0.66) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL17786576 | 0.89 | ABCG2 (0.60) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL926285 | 0.88 | MAPT (0.67) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL926030 | 0.88 | CSNK2A2 (0.64) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL17786357 | 0.88 | MAPT (0.69) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL17786494 | 0.87 | MAPT (0.69) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL12963109 | 0.86 | MAPT (0.58) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL17786621 | 0.86 | ACHE (0.55) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E | |
| SCHEMBL5126244 | 0.86 | KDM4E (0.64) | CSNK2A2CSNK2BCSNK2A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742033-B1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | ARMARON BIO PTY LTD (AU) | 2018-09-19 | — | — | EP | claimed |
| US-20140275156-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | NEUPROTECT PTY LTD (AU) | 2014-09-18 | — | — | US | claimed |
| EP-2742033-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | Neuprotect PTY Ltd (AU) | 2014-06-18 | — | — | EP | claimed |
| WO-2013020184-A9 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | NEUPROTECT PTY LTD (AU) | 2013-04-18 | — | — | WO | claimed |
| WO-2013020184-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | NEUPROTECT PTY LTD (AU) | 2013-02-14 | — | — | WO | claimed |
| EP-2742033-B1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | ARMARON BIO PTY LTD (AU) | 2018-09-19 | — | — | EP | disclosed |
| WO-2016083490-A1 | COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES | REMYND NV (BE) | 2016-06-02 | — | — | WO | disclosed |
| US-20140275156-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | NEUPROTECT PTY LTD (AU) | 2014-09-18 | — | — | US | disclosed |
| EP-2742033-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | Neuprotect PTY Ltd (AU) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013020184-A9 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | NEUPROTECT PTY LTD (AU) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013020184-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | NEUPROTECT PTY LTD (AU) | 2013-02-14 | — | — | WO | disclosed |
| US-8372866-B2 | 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain | ROTTAPHARM S.P.A. (IT) | 2013-02-12 | — | — | US | disclosed |
| EP-2268628-B1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM SPA (IT) | 2012-05-16 | — | — | EP | disclosed |
| US-20110003861-A1 | 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM S.P.A. (IT) | 2011-01-06 | — | — | US | disclosed |
| EP-2268628-A1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | Rottapharm S.p.A. (IT) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009109230-A1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003861-A1 | 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | NAT1, AADAC, OPRL1 | CSNK2A2 1153/4885CSNK2B 2039/4885CSNK2A1 1319/4885 |
| US-20140275156-A1 | FLAVONOID COMPOUNDS, AND METHODS OF USE THEREOF | BAX, MAPKAPK2, MAPK6 | CSNK2A2 2171/4885CSNK2B 1670/4885CSNK2A1 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.